ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
CuraSen doses first subjects in phase 1 trial of CST-2032 pharmaceutical-business-review
September 18, 2020CuraSen Therapeutics announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.
Pharma Sources Insight July 2025
